Naxitamab plus GM-CSF demonstrated strong antitumor activity and manageable toxicity in high-risk neuroblastoma patients, ...

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, ...

As of Wednesday, December 17, Greenwich LifeSciences, Inc.’s GLSI share price has surged by 5.19%, which has investors ...

The company has published significant consecutive studies in prestigious journals, showcasing advances in AI-driven drug ...

The first-in-human clinical phase I trial assessing the feasibility and safety of WDVAX, an immunostimulatory ...

Savara Inc. recently reported that the European Patent Office intends to grant a patent covering the liquid formulation of MOLBREEVI, its orally inhaled recombinant human GM-CSF for treating ...

-- 80% or greater reduction in metastatic breast cancer recurrence rate over 5 years of follow-up with a peak immune response at 6 months and well-tolerated safety profile. -- The PIS elicited a ...

A preliminary analysis of recurrence rates by two methods to estimate the reduction in recurrence rate shows an approximately 80% reduction in recurrence rate in the fully enrolled, 250 patient ...

VV169 saw complete clearance of disseminated myeloma tumors within 28 daysAnother dataset highlights Vyriad’s work in improved vector retargeting strategies in a comparative study of three methods for ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01 ...

NeuMap, the first single‑cell atlas of neutrophils, reveals conserved functional hubs across health, infection, and cancer, reshaping immunity.